a-D-赤藓-五呋喃糖苷,甲基2-脱氧-2-亚甲基- | 74160-60-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: a-D-赤藓-五呋喃糖苷,甲基2-脱氧-2-亚甲基-
• 英文名称: p-aminophenyl 6-phospho-α-D-mannopyranoside
• 英文别名: p-aminophenyl 6-phospo-α-D-mannopyranoside；papM6P；p-aminophenyl-6-phosphoro-α-D-mannopyranoside；[(2R,3S,4S,5S,6R)-6-(4-aminophenoxy)-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
• CAS: 74160-60-4
• 化学式: C₁₂H₁₈NO₉P
• 分子量: 351.25
• InChiKey: CJTXANSQOPINCC-GCHJQGSQSA-N

物化性质

• 沸点：
  680.7±65.0 °C(Predicted)
• 密度：
  1.698±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  172
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  p-nitrophenyl 6-phospho-α-D-mannopyranoside 在 palladium 10% on activated carbon 氢气 作用下， 生成 a-D-赤藓-五呋喃糖苷,甲基2-脱氧-2-亚甲基-
  参考文献：
  名称：

  Peptide-based carrier devices for stellate cells

  摘要：

  本发明涉及一种化合物，包括载体分子和与其连接的另一分子，所述另一分子至少为一个环肽，所述环肽在其环肽部分中包含至少一个编码细胞受体识别肽（RRP）的序列，且该化合物不是自然存在的受体激动剂或拮抗剂。优选的是，RRP是肝星状细胞（HSC）特异性受体或在疾病期间上调的受体。特别地，RRP可以是从PDGF受体、胶原VI型受体、细胞因子受体（如TGFβ、IFNα和白细胞介素1β）等受体组中选择的受体。优选的是，环肽的环状部分至少包括氨基酸序列RGD或KPT。该化合物可以用作活性靶向成分，制造用于治疗、预防或诊断纤维性疾病、硬化性疾病和慢性或急性炎症过程（如肾小球硬化、间质纤维化、肺纤维化、动脉粥样硬化、类风湿性关节炎、克隆氏病、溃疡性结肠炎、肾小球肾炎和脓毒症）的制药组合物，特别是用于靶向HSC。本发明还涉及包含上述化合物的制药组合物。

  公开号：

  US06844319B1

文献信息

• Receptor mediated endocytosis type diagnostic agents
  申请人：ADVANCED MAGNETICS, INC.

  公开号：EP0670167A1

  公开（公告）日：1995-09-06

  The present invention provides a new class of diagnostic agents which are comprised of arabinogalactan and a diagnostic label and which are capable of being distributed in vivo to a selected organ or tissue of a subject by a particular cell recognition and internalization pathway.

  本发明提供了一类新的诊断剂，它由阿拉伯半乳聚糖和诊断标签组成，能够在体内通过特定的细胞识别和内化途径分布到受试者的选定器官或组织。
• Peptide stellate carrier devices for stellate cells
  申请人：Poelstra Klaas

  公开号：US20050227916A1

  公开（公告）日：2005-10-13

  A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).

  一种化合物包括载体分子，其中载体分子与另一种分子相连，另一种分子是至少一种环肽，其中环肽部分包含至少一种编码细胞受体识别肽（RRP）的序列，但该化合物不是天然存在的受体激动剂或拮抗剂。最好，RRP 是肝星状细胞（HSC）的特异性受体或在疾病期间 HSC 上调的受体。RFP可选自PDGF受体、VI型胶原受体、细胞因子受体（如TGBβ、INFα和白细胞介素β）。肽的环状部分可包含至少一个氨基酸序列 RGD 或 KPT。这些化合物可用作活性靶向成分，用于制造药物组合物，以治疗、预防或诊断选自纤维化疾病、硬化性疾病和慢性或急性炎症过程的疾病，包括肾小球硬化、间质纤维化、肺纤维化、动脉粥样硬化、类风湿性关节炎、克罗恩病、溃疡性结肠炎、肾小球肾炎和败血症，特别是用于靶向造血干细胞。药物组合物含有上述化合物。
• Targeted Delivery of siRNA to Hepatocytes and Hepatic Stellate Cells by Bioconjugation
  作者：Lin Zhu、Ram I. Mahato

  DOI：10.1021/bc100346n

  日期：2010.11.17

  Previously, we successfully conjugated galactosylated poly(ethylene glycol) (Gal-PEG) to oligonucleotides (ODNs) via an acid labile ester linker (Zhu et al., Bioconjugate Chem. 2008, 19, 290-8). In this study, sense strands of siRNA were conjugated to Gal-PEG and mannose 6-phosphate poly(ethylene glycol) (M6P-PEG) for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells (HSCs), respectively. These siRNA conjugates were purified by ion exchange chromatography and verified by gel retardation assay. To evaluate their RNAi functions, the validated siRNA duplexes targeting firefly luciferase and transforming growth factor beta 1 (TGF-beta 1) mRNA were conjugated to Gal-PEG and M6P-PEG, and their gene silencing efficiencies were determined after transfection into HepG2 and HSC-T6 cells. The disulfide bond between PEG and siRNA was cleaved by dithiothreitol, leading to the release of intact siRNA. Both Gal-PEG-siRNA and M6P-PEG-siRNA conjugates could silence luciferase gene expression by about 40% without any transfection reagents, while the gene silencing effects reached more than 98% with the help of cationic liposomes at the same dose. Conjugation of TGF-beta 1 siRNA with Gal-PEG and M6P-PEG could silence endogenous TGF-beta 1 gene expression as well. In conclusion, these siRNA conjugates have the potential for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells for efficient gene silencing in vivo.
• Preparation and evaluation of hepatic stellate cell selective, surface conjugated, peroxisome proliferator-activated receptor-gamma ligand loaded liposomes
  作者：Gaurang Patel、Gitanjali Kher、Ambikanandan Misra

  DOI：10.3109/1061186x.2011.610800

  日期：2012.2

  Hepatic stellate cells (HSCs) activation leads to major fibrogenic response in liver fibrosis. Selective localization of drug to HSCs can provide effective antifibrotic therapy. Thus, objectives of study were to prepare peroxisome proliferator-activated receptor-gamma ligand (rosiglitazone) loaded mannose 6-phosphate modified human serum albumin (M6P-HSA) conjugated liposomes and evaluate pharmacokinetically and pharmacodynamically in rats for application of findings of studies in development of suitable and relevant product for treatment of liver fibrosis. The HSA was derivatized with mannose 6-phosphate and then coupled to optimized liposomes. Drug distribution in liver and other tissues after intravenous administration in carbon tetrachloride-induced liver fibrosis model rats was studied. Histopathological examination, estimation of biochemical markers, and grading of liver fibrosis was performed to evaluate pharmacodynamic efficacy of prepared formulation. The M6P-HSA conjugation to liposomes enhanced rosiglitazone liver uptake significantly (2.61 folds) and disappeared from systemic circulation at double rate. Favorable pharmacokinetics resulted in improved histopathological morphology, biochemical markers level, and decreased fibrosis grade. Hence, critical scrutiny of results suggested preferential and enhanced drug localization in pathogenic cells of liver providing a thinking which may result in development of product that can provide cure or at least prevention to this progressive disease necessitating liver transplant.
• EP0381742A4
  申请人：——

  公开号：EP0381742A4

  公开（公告）日：1991-04-24